Difference between revisions of "Antidepressants and other psychiatric medications in cancer care"
(Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' {| cl...") |
m (spacing) |
||
Line 1: | Line 1: | ||
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].''' | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].''' | ||
− | + | <br> | |
+ | <br> | ||
{| class="wikitable sortable" border="1" style="text-align:left;" | {| class="wikitable sortable" border="1" style="text-align:left;" | ||
!Medication | !Medication |
Revision as of 19:32, 9 July 2012
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Medication | Class | Indication | Starting dose | Target dose | Interactions | Side effects |
---|---|---|---|---|---|---|
Citalopram (Celexa) | SSRI | Anxiety
Depression |
10 mg | 20-40 mg | Mild 2D6 inhibition
Platelet dysfunction |
Nausea
fatigue |
Escitalopram (Lexapro) | SSRI | Anxiety
Depression |
5 mg | 10-20 mg | Mild 2D6 inhibition
Platelet dysfunction |
Nausea
fatigue |
Fluoxetine (Prozac) | SSRI | Depression
Anxiety |
10 mg | 20-60 mg | CYP450 2D6 inhibition
Very long half-life and multiple drug interactions |
Nausea
Sedation |
Sertraline (Zoloft) | SSRI | Depression
Anxiety |
50 mg | 150-200 mg | Weak 2D6 inhibition
Inhibits platelet function |
Nausea |
Venlafaxine (Effexor XR) | SNRI | Depression
Anxiety |
37.5 mg | 150 mg | 2D6 inhibition
Reduces platelet function |
Hypertension
Nausea Flu-like withdrawal |
Bupropion (Wellbutrin/Zyban) | Other antidepressant | Depression
Activating |
SR: 50-75 mg
XR: 150 mg |
150-300 mg | Strong 2D6 inhibition | Seizure risk (Black box)
Anxiety |
Mirtazapine (Remeron) | Other antidepressant | Anxiety
Depression Insomnia |
7.5 mg | 30-40 mg | Neutropenia reported
2D6 substrate |
Weight gain
Sedation |
Trazodone (Desyrel) | Other antidepressant | Anxiety
Insomnia |
25-50 mg | 50-100 mg | 3A4 substrate | Sedation
Nausea |
Desipramine (Norpramin) | Tricyclic | Depression
Anxiety Insomnia Boost pain control |
10-25 mg | Check blood levels and EKG | Strong 2D6 inhibition
Rare agranulocytosis |
Anticholinergic symptoms |
Imipramine (Tofranil) | Tricyclic | Depression
Anxiety Insomnia Boost pain control |
10-25 mg | Check blood levels and EKG | Strong 2D6 inhibition
Rare agranulocytosis |
Anticholinergic symptoms |
Nortriptyline (Pamelor) | Tricyclic | Depression
Anxiety Insomnia Boost pain control |
10-25 mg | Check blood levels and EKG | Strong 2D6 inhibition
Rare agranulocytosis |
Anticholinergic symptoms |
Gabepentin (Neurontin) | Anti-seizure | Pain control
Anxiety Insomnia |
100 mg | Large range from 300-3600 mg | Renal excreted (i.e. not metabolized) | Sedation |
Lamotrigine (Lamictal) | Anti-seizure | Elevates mood | 25 mg | 200 mg (for psych) | No weight gain
Other anti-seizure medications can double blood levels of lamotrigine |
Stevens-Johnson with any change in dose (Black box) |
Aripiprazole (Abilify) | Antipsychotic | Agitation
Anxiety |
5 mg | 15-20 mg | QTc prolongation may be less than other atypicals
No CYP450 inhibition Rare agranulocytosis |
Less weight gain
Extrapyramidal symptoms including akathisia and risk of tardive dyskinesia when mixed with prochlorperazine (Compazine) or metoclopramide (Reglan) |
Olanzapine (Zyprexa) | Antipsychotic | Agitation
Insomnia Anxiety |
2.5-5 mg | 10 mg | QTc prolongation | Sedation
Weight gain |
Quetiapine (Seroquel) | Antipsychotic | Nausea
Anxiety Insomnia Agitation |
25-50 mg | 100-300 mg | 3A4 substrate, limited drug/drug interactions
QTc prolongation |
Sedation
Weight gain |
Zolpidem (Ambien) | Insomnia | Insomnia | 5 mg | 5-10 mg | Alcohol interaction
Hepatic metabolism |
Sedation
Dizziness Parasomnias |
Information adapted from a table created by Christine Wittmann, MD and Laurie Rosenblatt, MD. Used with permission.